-
Patient-perspective and feasibility of home finger-prick testing to complement and facilitate large-scale research in rheumatology RMD Open (IF 6.2) Pub Date : 2024-04-01 Yaëlle R Besten, Laura Boekel, Maurice Steenhuis, Femke Hooijberg, Sadaf Atiqi, Maureen Leeuw, Erik H Vogelzang, Jim Keijser, Sofie Keijzer, Floris C Loeff, Martijn Gerritsen, Sander W Tas, Michael T Nurmohamed, Theo Rispens, Gertjan Wolbink
Background During the COVID-19 pandemic, we developed a digital research platform to longitudinally investigate COVID-19-related outcomes in patients with rheumatic diseases and healthy controls. We used home finger-prick testing in order to collect serum samples remotely and increase the overall efficiency of the platform. The aim of the present study was to evaluate the success rate of the finger
-
Classification of rheumatoid arthritis: is it time to revise the criteria? RMD Open (IF 6.2) Pub Date : 2024-04-01 Guenter Steiner, Patrick Verschueren, Lieve Van Hoovels, Paul Studenic, Xavier Bossuyt
Classification criteria have been developed for rheumatoid arthritis (RA) and other rheumatic diseases in order to gather a homogeneous patient population for clinical studies and facilitate the timely implementation of therapeutic measures. Although classification criteria are not intended to be used for diagnosis, they are frequently used to support the diagnostic process in clinical practice, including
-
Polygenic Risk Score Predicts Earlier-Onset Adult Systemic Lupus Erythematosus and First-Year Renal Diseases in a Taiwanese Cohort RMD Open (IF 6.2) Pub Date : 2024-04-01 Yen-Ju Chen, Tzu-Hung Hsiao, Ying-Cheng Lin, Wen-Juei Jeng, Chien-Lin Mao, Chia-Yi Wei, Yi-Chung Hsieh, Chih-Jen Huang, Mei-Hung Pan, I-Chieh Chen, Ching-Heng Lin, Yi-Ming Chen, Hwai-I Yang
Objectives This study aimed to develop a predictive model using polygenic risk score (PRS) to forecast renal outcomes for adult systemic lupus erythematosus (SLE) in a Taiwanese population. Methods Patients with SLE (n=2782) and matched non-SLE controls (n=11 128) were genotyped using Genome-Wide TWB 2.0 single-nucleotide polymorphism (SNP) array. PRS models (C+T, LDpred2, Lassosum, PRSice-2, PRS-continuous
-
Use of risk chart algorithms for the identification of psoriatic arthritis patients at high risk for cardiovascular disease: findings derived from the project CARMA cohort after a 7.5-year follow-up period RMD Open (IF 6.2) Pub Date : 2024-04-01 Jessica Polo y La Borda, Santos Castañeda, Elena Heras-Recuero, Fernando Sánchez-Alonso, Zulema Plaza, Carmen García Gómez, Ivan Ferraz-Amaro, Jesús Tomás Sanchez-Costa, Olga Carmen Sánchez-González, Ana Isabel Turrión-Nieves, Ana Perez-Alcalá, Carolina Pérez-García, Carlos González-Juanatey, Javier Llorca, Miguel Angel Gonzalez-Gay
Objective To assess the predictive value of four cardiovascular (CV) risk algorithms for identifying high-risk psoriatic arthritis (PsA) patients. Methods Evaluation of patients with PsA enrolled in the Spanish prospective project CARdiovascular in RheuMAtology. Baseline data of 669 PsA patients with no history of CV events at the baseline visit, who were followed in rheumatology outpatient clinics
-
Application of the 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease in a seronegative rheumatoid arthritis cohort RMD Open (IF 6.2) Pub Date : 2024-04-01 Helena Codes-Méndez, Luis Sainz, Hye Sang Park, Hèctor Corominas, Cesar Diaz-Torne
The 2023 ACR/EULAR Classification Criteria for calcium pyrophosphate deposition (CPPD) disease were recently approved.1 These criteria used an adjusted domain scoring system including demographic, clinical and radiological characteristics, and synovial fluid crystal analysis. Their development was driven by the necessity to address diagnostic challenges arising from variable clinical presentations
-
Analysis of belimumab prescription and outcomes in a 10-year monocentric cohort: is there an advantage with early use? RMD Open (IF 6.2) Pub Date : 2024-04-01 Chiara Tani, Dina Zucchi, Chiara Cardelli, Elena Elefante, Viola Signorini, Davide Schilirò, Giancarlo Cascarano, Luca Gualtieri, Anastasiya Valevich, Giulia Puccetti, Linda Carli, Chiara Stagnaro, Marta Mosca
Objective The objective is to evaluate perscriptions of belimumab (BEL), how these have changed over the years and their impact on clinical outcomes in patients with systemic lupus erythematosus (SLE). Methods This is a retrospective analysis of prospectively collected data. We retrieved demographic and clinical data and concomitant therapies at BEL starting (baseline). Disease activity was assessed
-
Understanding the psychosocial determinants of effective disease management in rheumatoid arthritis to prevent persistently active disease: a qualitative study RMD Open (IF 6.2) Pub Date : 2024-04-01 Nkasi Stoll, Mrinalini Dey, Sam Norton, Maryam Adas, Ailsa Bosworth, Maya H Buch, Andrew Cope, Heidi Lempp, James Galloway, Elena Nikiphorou
Background According to epidemiological studies, psychosocial factors are known to be associated with disease activity, physical activity, pain, functioning, treatment help-seeking, treatment waiting times and mortality in people with rheumatoid arthritis (RA). Limited qualitative inquiry into the psychosocial factors that add to RA disease burden and potential synergistic interactions with biological
-
Comparison of active tuberculosis occurrence associated with Janus kinase inhibitors and biological DMARDs in rheumatoid arthritis RMD Open (IF 6.2) Pub Date : 2024-04-01 Yun-Kyoung Song, Jaehee Lee, Junwoo Jo, Jin-Won Kwon
Objectives This study aimed to evaluate the risk of tuberculosis associated with the use of Janus kinase (JAK) inhibitors or biological disease-modifying antirheumatic drugs (bDMARDs) in patients diagnosed with rheumatoid arthritis (RA) in South Korea. Methods In this nationwide matched-cohort study, we retrospectively identified adult patients with new-onset RA from the National Health Insurance Service
-
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study RMD Open (IF 6.2) Pub Date : 2024-04-01 Maya H Buch, Deepak L Bhatt, Christina Charles-Schoeman, Jon T Giles, Ted Mikuls, Gary G Koch, Steven Ytterberg, Edward Nagy, Hyejin Jo, Kenneth Kwok, Carol A Connell, Karim Richard Masri, Arne Yndestad
Objectives Compare the risk of extended major adverse cardiovascular (CV) event (MACE) composite outcomes and component events in patients with rheumatoid arthritis (RA) treated with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in Oral Rheumatoid Arthritis Trial (ORAL) Surveillance. Methods Patients with RA aged ≥50 years and with ≥1 additional CV risk factor received tofacitinib 5 mg
-
Associations between life course longitudinal growth and hip shapes at ages 60–64 years: evidence from the MRC National Survey of Health and Development RMD Open (IF 6.2) Pub Date : 2024-04-01 Katherine Ann Staines, Fiona R Saunders, Alex Ireland, Richard M Aspden, Jennifer S Gregory, Rebecca J Hardy, Rachel Cooper
Objective We sought to examine associations between height gain across childhood and adolescence with hip shape in individuals aged 60–64 years from the Medical Research Council National Survey of Health and Development, a nationally representative British birth cohort. Methods Height was measured at ages 2, 4, 6, 7, 11 and 15 years, and self-reported at age 20 years. 10 modes of variation in hip shape
-
Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage RMD Open (IF 6.2) Pub Date : 2024-04-01 Alen Zabotti, Filippo Fagni, Laure Gossec, Ivan Giovannini, Michael Sticherling, Annarita Tullio, Xenofon Baraliakos, Gabriele De Marco, Salvatore De Vita, Enzo Errichetti, Luca Quartuccio, Ettore Silvagni, Josef S Smolen, Ilaria Tinazzi, Abdulla Watad, Georg Schett, Dennis G McGonagle, David Simon
Objective Subjects with subclinical psoriatic arthritis (PsA), defined as the presence of arthralgia in psoriasis (PsO), are at higher risk of PsA but scant real-world data exist. Our aims were to (1) estimate the probability of PsA development in subclinical PsA, (2) characterise subclinical PsA symptoms and (3) determine the clinical patterns at PsA diagnosis. Methods Patients with PsO, mainly subclinical
-
Utility of testing for third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in individuals who present with new musculoskeletal symptoms but have a negative second-generation anticyclic citrullinated peptide (anti-CCP2) antibody test RMD Open (IF 6.2) Pub Date : 2024-04-01 Andrea Di Matteo, Kulveer Mankia, Leticia Garcia-Montoya, Sana Sharrack, Laurence Duquenne, Jacqueline L Nam, Michael Mahler, Paul Emery
Objectives To investigate the role of third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in predicting progression to inflammatory arthritis (IA) in individuals with new musculoskeletal (MSK) symptoms and a negative second-generation anti-CCP antibody test (anti-CCP2−). Methods 469 anti-CCP2− individuals underwent baseline anti-CCP3 testing (QUANTA Lite CCP3; Inova Diagnostics)
-
Distinctive profile of monomeric and polymeric anti-SSA/Ro52 immunoglobulin A1 isoforms in saliva of patients with primary Sjögren’s syndrome and Sicca RMD Open (IF 6.2) Pub Date : 2024-04-01 Samantha Chiang, Tristan Grogan, Sarah Kamounah, Fang Wei, Nabihah Tayob, Ju Yeon Kim, Jin Kyun Park, David Akin, David A Elashoff, Anne Marie Lynge Pedersen, Yeong Wook Song, David T W Wong, David Chia
Objective Primary Sjögren’s syndrome (pSS) is the second most common chronic autoimmune connective tissue disease. Autoantibodies, immunoglobulin (IgG) anti-SSA/Ro, in serum is a key diagnostic feature of pSS. Since pSS is a disease of the salivary gland, we investigated anti-SSA/Ro52 in saliva. Methods Using a novel electrochemical detection platform, Electric Field-Induced Release and Measurement
-
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2 RMD Open (IF 6.2) Pub Date : 2024-04-01 Victoria Navarro-Compán, Sofia Ramiro, Atul Deodhar, Philip J Mease, Martin Rudwaleit, Christine de la Loge, Carmen Fleurinck, Vanessa Taieb, Michael F Mørup, Ute Massow, Jonathan Kay, Marina Magrey
Objective To assess how achievement of increasingly stringent clinical response criteria and disease activity states at week 52 translate into changes in core domains in patients with non-radiographic (nr-) and radiographic (r-) axial spondyloarthritis (axSpA). Methods Patients in BE MOBILE 1 and 2 achieving different levels of response or disease activity (Assessment of SpondyloArthritis International
-
Myocardial infarction in a population-based cohort of patients with biopsy-confirmed giant cell arteritis in southern Sweden RMD Open (IF 6.2) Pub Date : 2024-04-01 Pavlos Stamatis, Moman Aladdin Mohammad, Karl Gisslander, Peter A Merkel, Martin Englund, Carl Turesson, David Erlinge, Aladdin J Mohammad
Objectives To determine the incidence rate (IR) of myocardial infarction (MI), relative risk of MI, and impact of incident MI on mortality in individuals with biopsy-confirmed giant cell arteritis (GCA). Methods MIs in individuals diagnosed with GCA 1998–2016 in Skåne, Sweden were identified by searching the SWEDEHEART register, a record of all patients receiving care for MI in a coronary care unit
-
Correction: Diagnostic utility of serum IgG4 level in IgG4-related diseases: a comprehensive systematic review and meta-analysis RMD Open (IF 6.2) Pub Date : 2024-04-01 EULAR
Chang C, Chan T, Yu H, et al . Diagnostic utility of serum IgG4 level in IgG4-related diseases: a comprehensive systematic …
-
Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study RMD Open (IF 6.2) Pub Date : 2024-04-01 Hilde S Ørbo, Kristin H Bjørlykke, Joseph Sexton, Ingrid Jyssum, Anne T Tveter, Ingrid E Christensen, Siri Mjaaland, Tore K Kvien, Gunnveig Grødeland, Grete B Kro, Jørgen Jahnsen, Espen A Haavardsholm, Ludvig A Munthe, Sella A Provan, John T Vaage, Guro Løvik Goll, Kristin Kaasen Jørgensen, Silje Watterdal Syversen
Objectives To assess incidence, severity and predictors of COVID-19, including protective post-vaccination levels of antibodies to the receptor-binding domain of SARS-CoV-2 spike protein (anti-RBD), informing further vaccine strategies for patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive medication. Methods IMIDs on immunosuppressives and healthy controls (HC) receiving
-
Work-related physical strain and development of joint inflammation in the trajectory of emerging inflammatory and rheumatoid arthritis: a prospective cohort study RMD Open (IF 6.2) Pub Date : 2024-04-01 Bastiaan T van Dijk, Anna M P Boeren, Sarah J H Khidir, Nikolet K den Hollander, Annette H.M. van der Helm - van Mil
Objectives Rheumatoid arthritis (RA) mainly affects small joints. Despite the mechanical function of joints, the role of mechanical stress in the development of arthritis is insufficiently understood. We hypothesised that mechanical stress/physical strain is a risk factor for joint inflammation in RA. Therefore, we studied work-related physical strain in subjects with clinically suspected arthralgia
-
Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis: observational extension of the REDO trial RMD Open (IF 6.2) Pub Date : 2024-04-01 Nathan den Broeder, Lise Verhoef, Yaël A de Man, Marc R Kok, Rogier Thurlings, Wilfred van der Weele, Bart JF van den Bemt, Frank HJ van den Hoogen, Aatke van der Maas, Alfons A den Broeder
Background The REDO trial (REtreatment with Rituximab in RhEmatoid arthritis: Disease Outcome after Dose Optimisation) showed similar disease activity for retreatment with ultralow doses (200 mg and 500 mg per 6 months) compared with standard low-dose rituximab (RTX, 1000 mg per 6 months). We performed an observational extension study of the REDO trial to assess long-term effectiveness. Methods Patients
-
Correction: Significance of structural changes in the axial skeleton in patients with axial spondyloarthritis: how important are lesions in the sacroiliac joint? RMD Open (IF 6.2) Pub Date : 2024-04-01 EULAR
Braun J. Significance of structural changes in the axial skeleton in patients with axial spondyloarthritis: how important are lesions in the sacroiliac …
-
Incidence of collagen-induced arthritis is elevated by a high-fat diet without influencing body weight in mice RMD Open (IF 6.2) Pub Date : 2024-04-01 Jianhui Liang, Kuangyang Yang, Yanni Shen, Xiao Peng, Hao Tan, Lichu Liu, Qian Xie, Yan Wang
Obesity is recognised as a risk factor for triggering rheumatoid arthritis (RA), and it can worsen joint deformities1 and diminish the quality of life in patients with RA.2 The reduction of body weight in obese individuals is believed to alleviate RA symptoms.3 Body mass index (BMI) serves as the primary standard for evaluating obesity.4 An increase in BMI by 1 SD notably elevates the incidence rate
-
Recommendations for physical activity and exercise in persons living with Systemic Lupus Erythematosus (SLE): consensus by an international task force RMD Open (IF 6.2) Pub Date : 2024-04-01 Julien Blaess, Sophie Geneton, Thibaut Goepfert, Simone Appenzeller, Gabriel Bordier, Thomas Davergne, Yurilis Fuentes, Håvard Haglo, Karen Hambly, Dominique Kinnett-Hopkins, Kuei-Ying Su, Alexandra Legge, Linda Li, Anselm Mak, Ivan Padjen, Savino Sciascia, Saira Z Sheikh, Alberto Soriano-Maldonado, Manuel F Ugarte-Gil, Md Yuzaiful Md Yusof, Ioannis Parodis, Laurent Arnaud
Objective This international task force aimed to provide healthcare professionals and persons living with systemic lupus erythematosus (SLE) with consensus-based recommendations for physical activity and exercise in SLE. Methods Based on evidence from a systematic literature review and expert opinion, 3 overarching principles and 15 recommendations were agreed on by Delphi consensus. Results The overarching
-
Detection of hypophosphatasia in hospitalised adults in rheumatology and internal medicine departments: a multicentre study over 10 years RMD Open (IF 6.2) Pub Date : 2024-04-01 Guillaume Larid, Justine Vix, Pauline Preuss, François Robin, Alice Tison, Clémentine Delaveau, Faustine Krajewski, Béatrice Bouvard, Delphine Chu Miow Lin, Pascal Guggenbuhl, Yves Maugars, Alain Saraux, Francoise Debiais
Introduction Hypophosphatasia (HPP) is a rare genetic disease caused by loss-of-function mutations in the ALPL gene encoding the tissue non-specific alkaline phosphatase (ALP). Mild HPP is usually misdiagnosed in adult age. While an elevated serum ALP value draws more attention than a low value, low serum ALP should be better recognised and may lead to HPP detection. Methods Patients were selected
-
Dynamic change in red cell distribution width as a predictor for short-time mortality in dermatomyositis-associated rapid progressive interstitial lung disease RMD Open (IF 6.2) Pub Date : 2024-04-01 Fang Chen, Qiwen Jin, Yingfang Zhang, Guochun Wang, Guangtao Li, Xiaoming Shu
Aim We aimed to explore a new and readily available practical marker for rapidly progressive interstitial lung disease (RP-ILD) and poor short-term outcomes in patients with idiopathic inflammatory myopathies (IIM). Methods A total of 1822 consecutive patients with IIM between 2009 and 2021 were evaluated retrospectively. All proven cases of naïve ILD with complete medical records were included. Red
-
High prevalence of radiographic erosions in early, untreated PsA: results from the SpARRO cohort RMD Open (IF 6.2) Pub Date : 2024-04-01 Or Hen, Andrea Di Matteo, Sayam R Dubash, Gabriele De Marco, Ai Lyn Tan, Paul Emery, Richard J Wakefield, Dennis G McGonagle, Philip Helliwell, Helena Marzo-Ortega
Aims To investigate the prevalence and distribution of bone erosions in an early psoriatic arthritis (PsA) population using conventional radiography (CR) and to explore the agreement between CR and ultrasound (US) detected bone erosions. Methods Newly diagnosed, treatment naïve PsA patients fulfilling the ClASsification for Psoriatic Arthritis (CASPAR) classification criteria of ≤5 years symptom duration
-
Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR study RMD Open (IF 6.2) Pub Date : 2024-04-01 Violetta Dubovyk, Georgios K Vasileiadis, Tahzeeb Fatima, Yuan Zhang, Meliha Crnkic Kapetanovic, Alf Kastbom, Milad Rizk, Annika Söderbergh, Sizheng Steven Zhao, Ronald F van Vollenhoven, Merete Lund Hetland, Espen A Haavardsholm, Dan Nordström, Michael T Nurmohamed, Bjorn Gudbjornsson, Jon Lampa, Mikkel Østergaard, Marte Schrumpf Heiberg, Tuulikki Sokka-Isler, Gerdur Gröndal, Kristina Lend, Kim Hørslev-Petersen
Objective This report from the NORD-STAR (Nordic Rheumatic Diseases Strategy Trials and Registries) trial aimed to determine if obesity is associated with response to conventional and biological antirheumatic treatment in early rheumatoid arthritis (RA). Methods This report included 793 participants with untreated early RA from the randomised, longitudinal NORD-STAR trial, all of whom had their body
-
Impact of DMARD treatment and systemic inflammation on all-cause mortality in patients with rheumatoid arthritis and interstitial lung disease: a cohort study from the German RABBIT register RMD Open (IF 6.2) Pub Date : 2024-04-01 Tatjana Rudi, Vera Zietemann, Yvette Meissner, Angela Zink, Andreas Krause, Hanns-Martin Lorenz, Christian Kneitz, Martin Schaefer, Anja Strangfeld
Objectives To investigate the impact of disease activity and treatment with disease-modifying antirheumatic drugs (DMARDs) on all-cause mortality in patients with rheumatoid arthritis and prevalent interstitial lung disease (RA-ILD). Methods Patients with RA-ILD were selected from the biologics register Rheumatoid Arthritis: Observation of Biologic Therapy (RABBIT). Using time-varying Cox regression
-
Diagnostic accuracy in axial spondyloarthritis: a systematic evaluation of the role of clinical information in the interpretation of sacroiliac joint imaging RMD Open (IF 6.2) Pub Date : 2024-04-01 Tim Pohlner, Dominik Deppe, Katharina Ziegeler, Fabian Proft, Mikhail Protopopov, Judith Rademacher, Valeria Rios Rodriguez, Murat Torgutalp, Jürgen Braun, Torsten Diekhoff, Denis Poddubnyy
Objectives Radiography and MRI of the sacroiliac joints (SIJ) are relevant for the diagnosis and classification of patients with axial spondyloarthritis (axSpA). This study aimed to evaluate the impact of clinical information (CI) on the accuracy of imaging interpretation. Methods Out of 109 patients referred because of suspicion of axSpA with complete imaging sets (radiographs and MRI of SIJ), 61
-
Induction of regulatory T cells and efficacy of low-dose interleukin-2 in systemic sclerosis: interventional open-label phase 1–phase 2a study RMD Open (IF 6.2) Pub Date : 2024-04-01 François Barde, Roberta Lorenzon, Eric Vicaut, Sébastien Rivière, Patrice Cacoub, Carlotta Cacciatore, Michelle Rosenzwajg, Anne Daguenel-Nguyen, Olivier Fain, David Klatzmann, Arsène Mekinian
Background Systemic sclerosis (SSc) is a chronic autoimmune disease, with impaired immune response, increased fibrosis and endothelial dysfunction. Regulatory T cells (Tregs), which are essential to control inflammation, tissue repair and autoimmunity, have a decreased frequency and impaired function in SSc patients. Low-dose interleukin-2 (IL-2LD) can expand and activate Tregs and has, therefore,
-
The HLA region in ANCA-associated vasculitis: characterisation of genetic associations in a Scandinavian patient population RMD Open (IF 6.2) Pub Date : 2024-04-01 Christian Lundtoft, Ann Knight, Jennifer R S Meadows, Åsa Karlsson, Solbritt Rantapää-Dahlqvist, Ewa Berglin, Øyvind Palm, Hilde Haukeland, Iva Gunnarsson, Annette Bruchfeld, Mårten Segelmark, Sophie Ohlsson, Aladdin J Mohammad, Per Eriksson, Peter Söderkvist, Lars Ronnblom, Roald Omdal, Roland Jonsson, Kerstin Lindblad-Toh, Johanna Dahlqvist
Objective The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are inflammatory disorders with ANCA autoantibodies recognising either proteinase 3 (PR3-AAV) or myeloperoxidase (MPO-AAV). PR3-AAV and MPO-AAV have been associated with distinct loci in the human leucocyte antigen (HLA) region. While the association between MPO-AAV and HLA has been well characterised in East Asian
-
Correction: Validation of SPARCC MRI-RETIC e-tools for increasing scoring proficiency of MRI sacroiliac joint lesions in axial spondyloarthritis RMD Open (IF 6.2) Pub Date : 2024-04-01 EULAR
Maksymowych W, Hadsbjerg AEFEF, Østergaard M , et al . Validation of SPARCC MRI-RETIC e-tools for increasing scoring proficiency of MRI sacroiliac …
-
Correction: Association of nociplastic and neuropathic pain components with the presence of residual symptoms in patients with axial spondyloarthritis receiving biological disease-modifying antirheumatic drugs RMD Open (IF 6.2) Pub Date : 2024-04-01 EULAR
Al Mohamad F, Rios Rodriguez V, Haibel H, et al . Association of nociplastic and neuropathic pain components with the presence of residual symptoms in patients with axial spondyloarthritis receiving biological disease-modifying antirheumatic drugs. RMD Open 2024;10:e004009. doi: 10.1136/rmdopen-2023-004009 In this paper, the authors used the Widespread Pain Index (WPI) to identify nociplastic pain
-
Correction: Impact of filgotinib on pain control in the phase 3 FINCH studies RMD Open (IF 6.2) Pub Date : 2024-04-01 EULAR
Taylor PC, Kavanaugh A, Nash P, et al . Impact of filgotinib on pain control in the phase 3 FINCH studies. …
-
Correction: Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice RMD Open (IF 6.2) Pub Date : 2024-04-01 EULAR
Tanaka Y. Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice. RMD Open 2023;9:e003270. doi: 10.1136/rmdopen-2023-003270 Updates have been made to the 2nd paragraph under the following section: Patients with moderate to severe SLE who are unable to achieve at least LLDAS with existing SoC …
-
Learning imaging in axial spondyloarthritis: more than just a matter of experience RMD Open (IF 6.2) Pub Date : 2024-03-01 Felix Radny, Katharina Ziegeler, Iris Eshed, Juliane Greese, Dominik Deppe, Carsten Stelbrink, Robert Biesen, Hildrun Haibel, Valeria Rios Rodriguez, Judith Rademacher, Mikhail Protopopov, Fabian Proft, Kay Geert A Hermann, Denis Poddubnyy, Torsten Diekhoff, Sevtap Tugce Ulas
Objective Reliable interpretation of imaging findings is essential for the diagnosis of axial spondyloarthritis (axSpA) and requires a high level of experience. We investigated experience-dependent differences in diagnostic accuracies using X-ray (XR), MRI and CT. Methods This post hoc analysis included 163 subjects with low back pain. Eighty-nine patients had axSpA, and 74 patients had other conditions
-
Remission definitions guiding immunosuppressive therapy in rheumatoid arthritis: which is best fitted for the purpose? RMD Open (IF 6.2) Pub Date : 2024-03-01 Catia Duarte, Ricardo J O Ferreira, Paco M J Welsing, Johannes W G Jacobs, Laure Gossec, Pedro M Machado, Désirée van der Heijde, Jose Antonio Pereira da Silva
Objective To assess which definition of remission best predicts good radiographic outcome (GRO) and good functional outcome (GFO) in rheumatoid arthritis, focusing the updated American College of Rheumatology/European Alliance of Associations for Rheumatology criteria. Material and methods Meta-analyses of individual patient data (IPD) from randomised controlled trials (RCTs). Six definitions of remission
-
Effectiveness and safety of adalimumab compared with leflunomide in patients with Takayasu arteritis: a retrospective cohort study RMD Open (IF 6.2) Pub Date : 2024-03-01 Faustino Peron Filho, Andressa de Souza Moreira, Anna Larissa Faria Janes, Alexandre W S de Souza
Objective This study aims to evaluate the effectiveness and safety of adalimumab (ADA) compared with leflunomide (LEF) in patients with Takayasu arteritis (TAK). Method A retrospective cohort study was performed with the following inclusion criteria: the fulfilment of the 2022 American College Classification/European Alliance of Associations for Rheumatology criteria for TAK, age ≥18 years, and written
-
Validity of an ultrasonographic joint-specific scoring system in juvenile idiopathic arthritis: a cross-sectional study comparing ultrasound findings of synovitis with whole-body magnetic resonance imaging and clinical assessment RMD Open (IF 6.2) Pub Date : 2024-03-01 Nina Krafft Sande, Eva Kirkhus, Vibke Lilleby, Anders Høye Tomterstad, Anna-Birgitte Aga, Berit Flatø, Pernille Bøyesen
Objective To assess the validity of an ultrasonographic scoring system in juvenile idiopathic arthritis (JIA) by comparing ultrasound detected synovitis with whole-body MRI and clinical assessment of disease activity. Methods In a cross-sectional study, 27 patients with active JIA underwent clinical 71-joints examination, non-contrast enhanced whole-body MRI and ultrasound evaluation of 28 joints (elbow
-
Re-evaluating the mythical divide between traditional and novel cardiovascular risk factors in rheumatoid arthritis RMD Open (IF 6.2) Pub Date : 2024-03-01 Eirik Ikdahl, Mats Julius Stensrud
Cardiovascular (CV) risk factors for rheumatoid arthritis (RA) are conventionally classified as ‘traditional‘ and ‘novel‘. We argue that this classification is obsolete and potentially counterproductive. Further, we discuss problems with the common practice of adjusting for traditional CV risk factors in statistical analyses. These analyses do not target well-defined effects of RA on CV risk. Ultimately
-
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study RMD Open (IF 6.2) Pub Date : 2024-03-01 Laura C Coates, Laure Gossec, Miriam Zimmermann, May Shawi, Emmanouil Rampakakis, Natalie J Shiff, Alexa P Kollmeier, Xie L Xu, Peter Nash, Philip J Mease, Philip S Helliwell
Objective Evaluate long-term guselkumab effectiveness across Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-recognised domains/related conditions of psoriatic arthritis (PsA). Methods Post hoc analyses used data from DISCOVER-2 ([NCT03158285][1]) biologic/Janus-kinase inhibitor-naïve participants with active PsA (≥5 swollen/≥5 tender joints, C-reactive protein ≥0.6 mg/dL)
-
Incidence and clinical manifestations of giant cell arteritis in Spain: results of the ARTESER register RMD Open (IF 6.2) Pub Date : 2024-03-01 Delia Fernández-Lozano, Iñigo Hernández-Rodríguez, Javier Narvaez, Marta Domínguez-Álvaro, Eugenio De Miguel, Maite Silva-Díaz, Joaquín María Belzunegui, Clara Moriano Morales, Julio Sánchez, Eva Galíndez-Agirregoikoa, Vicente Aldaroso, Lydia Abasolo, Javier Loricera, Noemi Garrido-Puñal, Patricia Moya Alvarado, Carmen Larena, Vanessa Andrea Navarro, Joan Calvet, Ivette Casafont-Solé, Francisco Ortiz-Sanjuán
Objective This study aimed to estimate the incidence of giant cell arteritis (GCA) in Spain and to analyse its clinical manifestations, and distribution by age group, sex, geographical area and season. Methods We included all patients diagnosed with GCA between 1 June 2013 and 29 March 2019 at 26 hospitals of the National Health System. They had to be aged ≥50 years and have at least one positive results
-
Medication utilisation trends during pregnancy and factors influencing adverse pregnancy outcomes in patients with rheumatoid arthritis RMD Open (IF 6.2) Pub Date : 2024-03-01 Yeo-Jin Song, Soo-Kyung Cho, Yu-Seon Jung, Sun-Young Jung, Jihyun Keum, Eunwoo Nam, Yoon-Kyoung Sung, Dae Hyun Yoo
Objectives We aimed to investigate medication utilisation trends during pregnancy and identify factors associated with adverse pregnancy outcomes (APOs) in patients with rheumatoid arthritis (RA). Methods Female patients with RA aged 20–50 years were identified from the Korean national health insurance database between 2010 and 2020. Pregnancy episodes were divided into two groups according to pregnancy
-
Sex differences in cytokines and adipokines in obese patients with PsA and controls undergoing a weight loss intervention RMD Open (IF 6.2) Pub Date : 2024-03-01 Anton Jonatan Landgren, Charlotte A Jonsson, Annelie Bilberg, Björn Eliasson, Linda Torres, Mats Dehlin, Lennart Jacobsson, Inger Gjertsson, Ingrid Larsson, Eva Klingberg
Objective In this post hoc analysis of a previously published study, we compared cytokines and adipokine levels in women and men with psoriatic arthritis (PsA) at baseline (BL) and 6 months (M6) following a weight loss intervention. Methods Patients with PsA (n=41) between 25 and 75 years of age, with body mass index (BMI)≥33 kg/m2 were included in a weight loss intervention with a very low energy
-
Prediction of progressive fibrosing interstitial lung disease in patients with systemic sclerosis: insight from the CRDC cohort study RMD Open (IF 6.2) Pub Date : 2024-03-01 Min Hui, Xinwang Duan, Jiaxin Zhou, Mengtao Li, Qian Wang, Jiuliang Zhao, Yong Hou, Dong Xu, Xiaofeng Zeng
Background This study aims to establish a reliable prediction model of progressive fibrosing interstitial lung disease (PF-ILD) in patients with systemic sclerosis (SSc)-ILD, to achieve early risk stratification and to help better in preventing disease progression. Methods 304 SSc-ILD patients with no less than three pulmonary function tests within 6–24 months were included. We collected data at baseline
-
DWI scrolling artery sign for the diagnosis of giant cell arteritis: a pattern recognition approach RMD Open (IF 6.2) Pub Date : 2024-03-01 Luca Seitz, Susana Bucher, Lukas Bütikofer, Britta Maurer, Harald M Bonel, Fabian Lötscher, Pascal Seitz
Objectives To investigate the diagnostic accuracy of a pattern recognition approach for the evaluation of MRI scans of the head with diffusion-weighted imaging (DWI) in suspected giant cell arteritis (GCA). Methods Retrospectively, 156 patients with suspected GCA were included. The ‘DWI-Scrolling-Artery-Sign’ (DSAS) was defined as hyperintense DWI signals in the cranial subcutaneous tissue that gives
-
Baricitinib for refractory Takayasu arteritis: a prospective cohort study in a tertiary referral centre RMD Open (IF 6.2) Pub Date : 2024-03-01 Ziyue Zhou, Chenglong Fang, Li Wang, Jing Li, Yunjiao Yang, Li Zhang, Shangyi Jin, Xiaofeng Zeng, Xinping Tian
Objective To investigate the treatment efficacy and safety of baricitinib in patients with refractory Takayasu arteritis (TAK). Methods We performed a prospective cohort study in which baricitinib 4 mg daily was prescribed to patients with refractory TAK, combined with oral glucocorticoids (GCs). Results 10 patients with refractory TAK were enrolled with a median age of 28 (IQR=22–37) years, median
-
Pain sensitisation and joint inflammation in patients with active rheumatoid arthritis RMD Open (IF 6.2) Pub Date : 2024-03-01 Khaldoun Chaabo, Estee Chan, Toby Garrood, Zoe Rutter-Locher, Alex Vincent, James Galloway, Sam Norton, Bruce W Kirkham
Introduction Despite better therapies and strategies, many people with rheumatoid arthritis (RA) have persistent pain, often from abnormal pain processing, now termed nociplastic pain. However, RA patients with fibromyalgia (FM), a central nociplastic pain syndrome, also have power doppler ultrasound (PDUS+) joint inflammation. To understand the complex causes of pain, we performed clinical examination
-
Concordance and agreement between different activity scores in polymyalgia rheumatica RMD Open (IF 6.2) Pub Date : 2024-03-01 Justine D'Agostino, Aghiles Souki, Anne Lohse, Guillermo Carvajal Alegria, Emanuelle Dernis, Christophe Richez, Marie-Elise Truchetet, Daniel Wendling, Eric Toussirot, Aleth Perdriger, Jacques-Eric Gottenberg, Renaud Felten, Bruno Fautrel, Laurent Chiche, Pascal Hilliquin, Catherine Le Henaff, Benjamin Dervieux, Guillaume Direz, Isabelle Chary-Valckenaere, Divi Cornec, Dewi Guellec, Thierry Marhadour
Objective The C reactive protein polymyalgia rheumatica activity score (CRP-PMR-AS) is a composite index that includes CRP levels and was developed specifically for PMR. As treatments such as interleukin-6 antagonists can normalise CRP levels, the erythrocyte sedimentation rate (ESR) of PMR-AS, the clinical (clin)-PMR-AS and the imputed-CRP (imp-CRP)-PMR-AS have been developed to avoid such bias. Our
-
Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: a nationwide cohort study from the French Health Insurance Database (SNDS) RMD Open (IF 6.2) Pub Date : 2024-03-01 Léa Bastard, Pascal Claudepierre, Laetitia Penso, Emilie Sbidian, Laura Pina Vegas
Objective To assess the risk of serious infection associated with different targeted therapies for psoriatic arthritis (PsA) in real-world settings. Methods This nationwide cohort study used the administrative healthcare database of the French health insurance scheme linked to the hospital discharge database to identify all adults with PsA who were new users of targeted therapies (adalimumab, etanercept
-
Long-term efficacy of a 2-year MRI treat-to-target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission: 5-year follow-up of the IMAGINE-RA randomised trial RMD Open (IF 6.2) Pub Date : 2024-03-01 Signe Møller-Bisgaard, Kim Hørslev-Petersen, Lykke Midtbøll Ørnbjerg, Bo Ejbjerg, Merete Lund Hetland, Jakob Møllenbach Møller, Sabrina Mai Nielsen, Daniel Glinatsi, Mikael Boesen, Kristian Stengaard-Pedersen, Ole Rintek Madsen, Bente Jensen, Jan Alexander Villadsen, Ellen Margrethe Hauge, Oliver Hendricks, Hanne Lindegaard, Niels Steen Krogh, Anne Grethe Jurik, Henrik Thomsen, Robin Christensen, Mikkel
Objective To investigate whether a 2-year MRI treat-to-target strategy targeting the absence of osteitis combined with clinical remission, compared with a conventional treat-to-target strategy targeting clinical remission only (IMAGINE-rheumatoid arthritis (RA) trial) improves clinical and radiographic outcomes over 5 years in patients with RA in clinical remission. Methods IMAGINE-more was an observational
-
Internalisation of neutrophils extracellular traps by macrophages aggravate rheumatoid arthritis via Rab5a RMD Open (IF 6.2) Pub Date : 2024-03-01 Haixin Ye, Qian Yang, Huaxia Guo, Xing Wang, Lifang Cheng, Bingqi Han, Mukeng Hong, Fopei Ma, Meng Li, Xianghui Wu, Feilong Chen, Junqing Zhu, Shixian Chen, Songyuan Zheng, Juan Li
Objectives Although elevated levels of neutrophil extracellular traps (NETs) have been reported in patients with rheumatoid arthritis (RA), the role of NETs in RA and the relationship between NETs and macrophages in the pathogenesis of RA requires further research. Here, we sought to determine the role of NETs in RA pathogenesis and reveal the potential mechanism. Methods Neutrophil elastase (NE) and
-
Impact of filgotinib on pain control in the phase 3 FINCH studies RMD Open (IF 6.2) Pub Date : 2024-03-01 Peter C Taylor, Arthur Kavanaugh, Peter Nash, Janet Pope, Georg Pongratz, Bruno Fautrel, Rieke Alten, Ken Hasegawa, Shangbang Rao, Dick de Vries, Pieter-Jan Stiers, Chris Watson, Rene Westhovens
Objective This post hoc analysis of the FINCH 1–3 ([NCT02889796][1], [NCT02873936][2] and [NCT02886728][3]) studies assessed specific effects of filgotinib on pain control and their relationship with other aspects of efficacy in patients with rheumatoid arthritis (RA). Methods Assessments included: residual pain responses of ≤10 and ≤20 mm on a 100 mm visual analogue scale (VAS); the proportion of
-
The development and initial validation of IgG4-related disease damage index: a consensus report from Chinese IgG4-RD Consortium RMD Open (IF 6.2) Pub Date : 2024-03-01 Linyi Peng, Jingna Li, Jiaxin Zhou, Yunyun Fei, lingli Dong, Yan-Ying Liu, Dingding Zhang, Yanhong Wang, Shuhong Chi, Fang Wang, Yunxia Hou, Xiaoping Hong, Hongsheng Sun, Yujin Ye, Nan Che, Rong Zhang, Changyan Liu, Zongfei Ji, Wenjia Sun, Cheng Zhao, Ning Ma, Yamin Lai, Mengtao Li, Yan Zhao, Xiaofeng Zeng, Liwei Lu, Wen Zhang
Objective To develop and conduct an initial validation of the Damage Index for IgG4-related disease (IgG4-RD DI). Methods A draft of index items for assessing organ damages in patients with IgG4-RD was generated by experts from the Chinese IgG4-RD Consortium (CIC). The preliminary DI was refined using the Delphi method, and a final version was generated by consensus. 40 IgG4-RD cases representing four
-
Disease activity trajectories from childhood to adulthood in the population-based Nordic juvenile idiopathic arthritis cohort RMD Open (IF 6.2) Pub Date : 2024-03-01 Veronika Rypdal, Mia Glerup, Martin Rypdal, Ellen Arnstad, Kristiina Aalto, Lillemor Berntson, Anders Fasth, Troels Herlin, Charlotte Myrup, Suvi Peltoniemi, Marite Rygg, Ellen Berit Nordal
Objectives To identify long-term disease activity trajectories from childhood to adulthood by using the clinical Juvenile Arthritis Disease Activity Score (cJADAS10) in juvenile idiopathic arthritis (JIA). Second, to evaluate the contribution of the cJADAS10 components and explore characteristics associated with active disease at the 18-year follow-up. Methods Patients with onset of JIA in 1997–2000
-
Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation RMD Open (IF 6.2) Pub Date : 2024-03-01 Abhishek Abhishek, Matthew Grainge, Tim Card, Hywel C Williams, Maarten W Taal, Guruprasad P Aithal, Christopher P Fox, Christian D Mallen, Matthew D Stevenson, Georgina Nakafero, Richard Riley
Background Sulfasalazine-induced cytopenia, nephrotoxicity and hepatotoxicity is uncommon during long-term treatment. Some guidelines recommend 3 monthly monitoring blood tests indefinitely during long-term treatment while others recommend stopping monitoring after 1 year. To rationalise monitoring, we developed and validated a prognostic model for clinically significant blood, liver or kidney toxicity
-
Hyperactivation and altered selection of B cells in patients with paediatric Sjogren’s syndrome RMD Open (IF 6.2) Pub Date : 2024-03-01 Alessandra Boni, Rebecca Nicolai, Ivan Caiello, Francesca Marinaro, Luciapia Farina, Denise Pires Marafon, Rita Carsetti, Fabrizio De Benedetti, Claudia Bracaglia, Emiliano Marasco
Objectives Paediatric Sjögren’s syndrome (pSS) is a rare chronic autoimmune disorder, characterised by inflammation of exocrine glands. B cell hyperactivation plays a central role in adult-onset Sjogren. This study was designed to analyse B cell and T cell phenotype, levels of BAFF, and selection of autoreactive B cells in patients with pSS. Methods A total of 17 patients diagnosed with pSS and 13
-
Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System RMD Open (IF 6.2) Pub Date : 2024-03-01 Hugo Jourdain, Léa Hoisnard, Emilie Sbidian, Mahmoud Zureik
Objectives Biosimilar-originator equivalence has been demonstrated in phase 3 trials in a few indications of infliximab, etanercept and adalimumab. The objective of our study was to compare the persistence and safety of biosimilars versus originators in all the licensed indications of these molecules. Methods We used data from the French National Health Data System (SNDS), covering 99% of the French
-
Comparison of the efficacy and safety of a proposed biosimilar MSB11456 with tocilizumab reference product in subjects with moderate-to-severe rheumatoid arthritis: results of a randomised double-blind study RMD Open (IF 6.2) Pub Date : 2024-02-01 Anna Zubrzycka-Sienkiewicz, Kamilla Klama, Martin Ullmann, Corinne Petit-Frere, Peter Baker, Joëlle Monnet, Andras Illes
Objective To evaluate the efficacy, immunogenicity and safety of the proposed biosimilar MSB11456 versus European Union (EU)-approved tocilizumab reference product in patients with rheumatoid arthritis (RA) in a multicentre, randomised, double-blind, multinational, parallel-group study ([NCT04512001][1]). Methods Adult patients with moderate-to-severe active RA and inadequate clinical response to ≥1
-
Epidemiology and clinical characteristics of biopsy-confirmed adult-onset IgA vasculitis in southern Sweden RMD Open (IF 6.2) Pub Date : 2024-02-01 Michaela Thalen, Karl Gisslander, Mårten Segelmark, Jacob Sode, David Jayne, Aladdin J Mohammad
Objective Immunoglobulin A vasculitis (IgAV) is the most prevalent primary childhood vasculitis in Sweden, but is considerably rarer in adults. This study aims to describe the epidemiology, clinical characteristics and renal outcome of adult-onset IgAV in Skåne, Sweden. Methods The study area consisted of Skåne, the southernmost region of Sweden, with a population ≥18 years of 990 464 on 31 December
-
Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index RMD Open (IF 6.2) Pub Date : 2024-02-01 Silvia Rosina, Alessandro Consolaro, Angela Pistorio, Ana Rebollo-Giménez, Claudia Bracaglia, Pavla Dolezalova, Ana Guilaisne Bernard-Medina, Troels Herlin, Maria Trachana, Veronika Vargová, Carine Wouters, Laura Carenini, Nicolino Ruperto, Angelo Ravelli
Objectives To develop and validate the cut-offs in the Juvenile DermatoMyositis Activity Index (JDMAI) to distinguish the states of inactive disease (ID), low disease activity (LDA), moderate disease activity (MDA) and high disease activity (HDA) in children with juvenile dermatomyositis (JDM). Methods For cut-off definition, data from 139 patients included in a randomised clinical trial were used